Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 3/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.32 |
| ▸ | RELA | Q04206 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
| ▸ | GUSB | P08236 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17227886 | 1.00 | HTR2C (0.33) | HTR2CHTR2AHTR2BNFKB1NFKB2 | |
| SCHEMBL17220875 | 1.00 | HTR2C (0.33) | HTR2CHTR2AHTR2BNFKB1NFKB2 | |
| SCHEMBL17227896 | 0.79 | CYP19A1 (0.36) | HTR2CHTR2B | |
| SCHEMBL17220879 | 0.79 | CYP19A1 (0.36) | HTR2CHTR2B | |
| SCHEMBL17227902 | 0.77 | MAOB (0.40) | NFKB1NFKB2RELATP53 | |
| SCHEMBL15954244 | 0.77 | MAOB (0.40) | NFKB1NFKB2RELATP53 | |
| SCHEMBL25201323 | 0.77 | MAOB (0.40) | NFKB1NFKB2RELATP53 | |
| SCHEMBL643216 | 0.77 | KDM1A (0.38) | HTT | |
| SCHEMBL15953692 | 0.76 | HTR2A (0.36) | HTR2CHTR2AHTR2B | |
| SCHEMBL29507309 | 0.76 | HTR2C (0.38) | HTR2CHTR2BTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11952358-B2 | Flavan-3-ol analogs and anti-inflammatory activity | HONG KONG BAPTIST UNIVERSITY (CN) | 2024-04-09 | — | — | US | disclosed |
| US-20230159482-A1 | FLAVAN-3-OL ANALOGS AND ANTI-INFLAMMATORY ACTIVITY | HONG KONG BAPTIST UNIVERSITY (CN) | 2023-05-25 | — | — | US | disclosed |
| US-20230159482-A1 | FLAVAN-3-OL ANALOGS AND ANTI-INFLAMMATORY ACTIVITY | HONG KONG BAPTIST UNIVERSITY (CN) | 2023-05-25 | — | — | US | disclosed |
| US-20230159482-A1 | FLAVAN-3-OL ANALOGS AND ANTI-INFLAMMATORY ACTIVITY | HONG KONG BAPTIST UNIVERSITY (CN) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11952358-B2 | Flavan-3-ol analogs and anti-inflammatory activity | IL1A, IL6, IL1B | HTR2C 2780/4885HTR2A 1979/4885HTR2B 3193/4885 |
| US-20230159482-A1 | FLAVAN-3-OL ANALOGS AND ANTI-INFLAMMATORY ACTIVITY | IL1A, IL6, IL1B | HTR2C 2780/4885HTR2A 1979/4885HTR2B 3193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.